
ã¢ã¡ãªã«ã§ã¯èµ·æºæ ªã¯ã¯ãã³ã䜿çšäžå¯ã«ãªã£ãã®ã§ãæ£åŒæ¿èªãããŠããã³ããã¯ã¯ãã³ã¯ãªã!?
4æ18æ¥ä»ã®ãªãªãŒã¹ã§ãFDAã¯ã1䟡ïŒèµ·æºæ ªïŒã®ã³ããã¯ã¯ãã³ã¯ãã¢ã¡ãªã«ã§ã®äœ¿çšãèš±å¯ãããªããªã£ãããšçºè¡šããŸããã
FDAãçºè¡šãã2023幎4æ18æ¥ä»ã®ãªãªãŒã¹
以äžãFDAãçºè¡šãããªãªãŒã¹ããã®åŒçšã§ãã
The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.
ã¢ãã«ã瀟ããã³Pfizer-BioNTech瀟 ã® COVID-19ã1䟡ïŒèµ·æºæ ªïŒ ã¯ã¯ãã³ã¯ãã¢ã¡ãªã«ã§ã®äœ¿çšãèªå¯ãããªããªããŸããã
What You Need to Know:
Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of a bivalent vaccine may receive a single dose of a bivalent vaccine.
以åã«1䟡ïŒèµ·æºæ ªïŒã® COVID-19ã¯ã¯ãã³ãæ¥çš®ããããšãããããŸã 2䟡ã¯ã¯ãã³ãæ¥çš®ããŠããªãã»ãšãã©ã®äººã¯ã幎霢ã«å¿ããŠ2䟡ã¯ã¯ãã³ã 1 åæ¥çš®ããããšãã§ããŸãã
Most individuals who have already received a single dose of the bivalent vaccine are not currently eligible for another dose. The FDA intends to make decisions about future vaccination after receiving recommendations on the fall strain composition at an FDA advisory committee in June.
2䟡ã¯ã¯ãã³ã®ååæ¥çš®ãåããã»ãšãã©ã®äººã¯ãçŸåšãæ¬¡ã®æ¥çš®ãåããè³æ ŒããããŸããã FDA ã¯ã6 æã« éå¬ããFDA è«®åå§å¡äŒã§ãç§ã®èæ ªçµæã«é¢ããæšå¥šäºé ãåãåã£ãåŸãä»åŸã®ã¯ã¯ãã³æ¥çš®ã«ã€ããŠæ±ºå®ãäžãäºå®ã§ãã
Individuals 65 years of age and older who have received a single dose of a bivalent vaccine may receive one additional dose at least four months following their initial bivalent dose.
2 䟡ã¯ã¯ãã³ã 1åæ¥çš®ãã 65 æ³ä»¥äžã®äººã¯ãæåã®2 䟡ã¯ã¯ãã³æ¥çš®ããå°ãªããšã 4 ãæåŸã« 1 åã®è¿œå æ¥çš®ãåããããšãã§ããŸãã
Most unvaccinated individuals may receive a single dose of a bivalent vaccine, rather than multiple doses of the original monovalent mRNA vaccines.
ã¯ã¯ãã³æ¥çš®ãåããŠããªãã»ãšãã©ã®äººã¯ã1 䟡 mRNA ã¯ã¯ãã³ïŒèµ·æºæ ªïŒãè€æ°åæ¥çš®ããã®ã§ã¯ãªãã2䟡ã¯ã¯ãã³ã1 åæ¥çš®ããã°ããã
ã¢ã¡ãªã«ã§ãç·æ¥äœ¿çšèš±å¯ã®ã¯ã
ã¢ã¡ãªã«ã§äœ¿çšäžå¯ãšãªã£ãèµ·æºæ ªã¯ã¯ãã³ã¯ã2021幎8æã«æ£åŒæ¿èªã«ãªã£ããšçºè¡šãããŠããããç·æ¥äœ¿çšèš±å¯ã®èµ·æºæ ªã¯ã¯ãã³ã䜿ããç¶ããŠããã®ã§ãããããè¬ãæ®ããŸãïŒäžèšåç §ïŒã
ãªãã¯ãã³æ ªå¯Ÿå¿ã¯ã¯ãã³ã¯ãã¢ã¡ãªã«ã§ãæ£åŒæ¿èªã§ã¯ãªãç·æ¥äœ¿çšèš±å¯ã§ãã
æ¥æ¬ã§ã®ç¹äŸæ¿èªã®å¯©æ»ããããŠã¹ã®ããŒã¿ããåºãŠããŸããã§ããã
åè¿°ã®ãªãªãŒã¹ã«ã¯ãå®å šæ§ãæå¹æ§ã«ã€ããŠã¯èµ·æºæ ªãBA.1ã®ããŒã¿ããããåã補æ³ã§äœãããŠããããBA.45ã®å®å šæ§ãæå¹æ§ã«ãã€ãªãããšæžãããŠããŸãã
The data accrued with the investigational Pfizer-BioNTech bivalent COVID-19 vaccine (original and omicron BA.1) and with the monovalent Pfizer-BioNTech COVID-19 Vaccine are relevant to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.
ããã©ããèµ·æºæ ªã¯ã¯ãã³ãšãªãã¯ãã³æ ªå¯Ÿå¿ã¯ã¯ãã³ã¯æ·»å å€ãéããŸããããããããèµ·æºæ ªã¯ã¯ãã³ã®å®å šæ§ã販売åŸã«ãã¡ããšè©äŸ¡ãããŠããŸããã
ã¢ã¡ãªã«ã§ã®ç·æ¥äœ¿çšèš±å¯ïŒEUAïŒã«ã€ããŠã¯ãFDAã®ãã¡ã¯ãã·ãŒãã«äžèšã®ããã«æžãããŠããŸãã

EUAã®ã¯ã¯ãã³ã¯ãFDAãæ£åŒã«æ¿èªãŸãã¯èªå¯ãã補è¬ãšåæ§ãªå¯©æ»ãåããŠããŸãããCOVID-19ã®ãã³ãããã¯æã«COVID-19ãäºé²ããããã«æå¹ã§ãããæœåšçãªãããã£ãããã補åã®æ¢ç¥ããã³æœåšçãªãªã¹ã¯ãäžåãå Žåã«äœ¿çšã§ãããšãããŸãã
ããã«ãEUA ã¯ãCOVID-19 EUA 宣èšãæ£åœåãããŠããéãEUA宣èšãçµäºãŸãã¯åãæ¶ãããªãéãæå¹ãã ãšæžãããŠããŸãã
ã¢ã¡ãªã«ã§ã¯ãã»ãšãã©ã®äººããã¹ã¯ãå€ããã¯ã¯ãã³ãæ¥çš®ããããšããäººãæ¥æ¬ã»ã©å€ããããŸããããããã³ãããã¯ã§ã¯ãªããšæã£ãŠããããã«èŠããŸãããããã§ããŸã ãEUA宣èšã¯åãæ¶ãããŠããªãããã§ãã
ããã¯ãæ¥æ¬ã§ã®5é¡ãžã®ç§»è¡ãšåããããªããšã§ã¯ãªãã§ããããïŒäžèšåç §ïŒã
æ¬æ¥ãªãã2023幎1æ27æ¥ã®åçç§åŠå¯©è°äŒã§ãåœæ°ã®çåœåã³å¥åº·ã«é倧ãªåœ±é¿ãäžããããããããç¶æ ãšã¯èããããªãããšãããæ°åã€ã³ãã«ãšã³ã¶çææçã«ã¯è©²åœããªããã®ããšãããæç¹ã§ãæ³ã®é©çšå¯Ÿè±¡ã§ãªããªã£ãŠããã¯ãã§ããããã©ããååŽå€§è£ãæ£åŒãªçºè¡šãããŠããŸããã5é¡ã«æ Œäžãããããã«èŠããããŠãæ ŒäžãããããšããŠããã®ã§ããããããããšã§ãç¹äŸæ¿èªã®ã¯ã¯ãã³ã䜿ãç¶ããããšããŠããã®ã ãšæããŸãããªã䜿ãç¶ããã®ãã¯ããããŸãããåšåº«ãåŠåããããããã補è¬äŒç€Ÿãšã®å¥çŽã®åé¡ãªã®ãããããŸããã
ã¢ã¡ãªã«ã§ããç·æ¥äœ¿çšèš±å¯ã®ã¯ã¯ãã³ã䜿ãç¶ããããŠãããšããããšã¯ãEUA宣èšãåãæ¶ãããŠããªããšããããšã§ãããã
ããã©ããã¢ã¡ãªã«ã𿥿¬ã§å€§ããéãããšã¯ãã¢ã¡ãªã«ã§ã¯çºè¡šããªããŠãããç·æ¥äºæ ã§ã¯ãªãããšã¯æããšããèªåãã¡ã§èããŠè¡åããŠããããšã§ããã ããã¯ã¯ãã³æ¥çš®ããæ¥æ¬ã»ã©ããŠããŸããã
ä»åãFDAããã®ãããªçºè¡šãããã®ã¯ãäœè¿·ããŠããæ¥çš®çãåäžãããçãããããšãèªå£²æ°èã®èšäºã«ã¯æžãããŠããŸãã
ç±³ã®ã³ããã¯ã¯ãã³æ¥çš®ãããªãã¯ãã³æ ªãæ¹è¯åã«çµ±äžâŠåŸæ¥æ ªå¯Ÿå¿ã¯äœ¿çšåããã
2023/04/19 10:40ãèªå£²æ°è
ç±³é£åå»è¬åå±ïŒïŒŠïŒ€ïŒ¡ïŒã¯ïŒïŒæ¥ãç±³ãã¡ã€ã¶ãŒè£œãšç±³ã¢ãã«ãè£œã®æ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®æ¥çš®ããå€ç°æ ªããªãã¯ãã³æ ªãã«å¯Ÿå¿ããæ¹è¯åã«çµ±äžãããšçºè¡šããã䜵åããŠããåŸæ¥æ ªå¯Ÿå¿ã®ã¯ã¯ãã³ã¯äœ¿çšãåãããããç°¡ç¥åããŠããããããããããšã§ãïŒå²çšåºŠãšäœè¿·ããŠããæ¥çš®çãåäžãããçããããã
äž¡ç€Ÿã®æ¹è¯åã¯ã¯ãã³ã¯ïŒŠïŒ€ïŒ¡ãæšå¹ŽïŒæã«äœ¿çšãèš±å¯ãããã¯ãå ç«äžå šãé«éœ¢è ãé€ã倧éšåã®äººã¯ãæ¹è¯åã¯ã¯ãã³ã®ïŒåã®æ¥çš®ã§ååãªå ç«åå¿ãåŸããããšããŠãããæ åœå¹¹éšã®ããŒã¿ãŒã»ããŒã¯ã¹å士ã¯ãç°¡ç¥åãå°æ¥ã®æ¥çš®ãä¿é²ããããšè¿°ã¹ãã
äžæ¹ãæ¥æ¬ã®æ¥çš®çãèŠãŠã¿ãŸãããã

ãªãã¯ãã³æ ªå¯Ÿå¿ã¯ã¯ãã³ã®æ¥çš®çã¯ãçŽ4å²ãšãªã£ãŠããŸãã
åèïŒç¹äŸæ¿èªãšã¯
ãããå»è¬åãå»çæ©åšçã®å質ãæå¹æ§åã³å®å šæ§ã®ç¢ºä¿çã«é¢ããæ³åŸç¬¬14 æ¡ã®ïŒç¬¬ïŒé ã®èŠå®ã«åºã¥ãã
ãããïŒïŒçŸç ã®ãŸã延鲿¢çã®ããã«ç·æ¥ã®äœ¿çšãå¿ èŠã
ãããïŒïŒåœè©²å»è¬åã®äœ¿çšä»¥å€ã«é©åãªæ¹æ³ããªãã
ãããïŒïŒæµ·å€ã§è²©å£²çãèªããããŠããã
ãããšããèŠä»¶ãæºããå»è¬åã«ã€ããŠãæ¿èªç³è«è³æã®ãã¡èšåºè©Šéšä»¥å€ã®ãã®ãæ¿èªåŸã®æåºãšããŠãè¯ãçãšããŠãç¹äŸçãªæ¿èªãããå¶åºŠã§ãã
æ¥çš®åŸã®æ»äº¡ãå¥åº·è¢«å®³ã倿°å ±åãããå®å
šæ§ã«çåãåºãŠããã¯ã¯ãã³ããä»ã®ç¶æ³ã§ç·æ¥ã®äœ¿çšãå¿
èŠã ãšæããŸããïŒ
4æ22æ¥ãŸã§åéäžã®ããã³ã¡
ææ¥4æ22æ¥ãŸã§ã5æä»¥éãã³ããã¯ã¯ãã³æ¥çš®ã®å¯Ÿè±¡ãšãªããåºç€çŸæ£ã®ãã人ãã®å®çŸ©ãªã©ã«é¢ããããã³ã¡ãåéããŠããŸããæ¥çš®åŸã®æ»äº¡ãå¥åº·è¢«å®³ãªã©ãææžå¶åºŠã§èªå®ãããäºäŸã¯åºç€çŸæ£ã®ãã人ãå€ãããšãç¹äŸæ¿èªã®ã¯ã¯ãã³ããªã䜿ãç¶ããã®ãããªãå®å šæ§ãæ€èšŒããã«æ¥çš®ãç¶ããã®ããæèŠãèšããã£ã³ã¹ã§ãã
ãã®ãŸãŸã§ã¯æ¥çš®åžãéãããŠããŸãã®ã§ãé«éœ¢è ãåºç€çŸæ£ã®ããæ¹ã¯ãªã¹ã¯ã®èª¬æãåããªããŸãŸãæ¥çš®ããŠããŸãå¯èœæ§ãé«ãã§ãããã
äžèšã®ããŒãžã«ãããã©ãŒã ããæèŠãéãããšãã§ããå¿åã§ã®æåºãå¯èœã§ãã
æèŠã®åéã¯ã4æ22æ¥22æ30åãŸã§ã§ãïŒ